Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8WUF8
UPID:
F172A_HUMAN
Alternative names:
Protein FAM172A
Alternative UPACC:
Q8WUF8; B2R7C6; B4DJ14; B4DLG5; Q9H0U8
Background:
Cotranscriptional regulator FAM172A, also known as Protein FAM172A, is pivotal in the regulation of alternative splicing. It achieves this by interacting with key proteins AGO2 and CHD7, essential for stabilizing protein-protein interactions at the chromatin-spliceosome interface. Additionally, FAM172A may exhibit hydrolase activity, further underscoring its multifunctional role in cellular processes.
Therapeutic significance:
Understanding the role of Cotranscriptional regulator FAM172A could open doors to potential therapeutic strategies. Its involvement in the critical process of alternative splicing highlights its potential as a target for therapeutic intervention in diseases where splicing anomalies are a factor.